U.S. Physical Therapy (USPH) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

$0.75

Estimate

$0.84

Surprise

-11.2%

Score at report (before → after)

4.8 → 4.5/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

U.S. Physical Therapy (USPH) missed the $0.84 estimate with diluted EPS of $0.75 — a large 11.2% shortfall. TrendMatrix's engine moved from Buy (Wait) (4.8/10) to Sell at 4.5/10 after the report.

TrendMatrix currently rates USPH Sell at 4.4/10.

0 of the last 4 quarters beat the estimate; this quarter's -11.2% surprise compares with a -5.7% four-quarter average. Next scheduled report: 2026-11-04.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$79.35

Price target

$82.65

Stop

$74.99

Upside to target

+4.2%

Reward-to-risk

0.8:1

Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Care Facilities

Market cap

$1.18B

P/E (fwd)

23.5

P/E (ttm)

466.8

52-week range

$58.19–$93.50

Off 52-week high

15.1%

RSI (14)

58

Volume vs avg

0.56×

Score today

4.4/10